NEW YORK — Molecular diagnostics startup Naveris said on Tuesday that it has closed a $17 million Series A financing round. The firm plans to use the funding to advance its liquid biopsy technology for the detection of virus-related cancers.
The financing round was led by Gurnet Point Capital, which was joined by R-Cubed Capital Partners and Sky Ventures Group. Naveris previously raised around $2 million in seed funding.